Multibagger stock: Strides Pharma Sciences receives USFDA approval
Multibagger stock: Strides Pharma Sciences receives USFDA approval

Multibagger stock: Strides Pharma Sciences receives USFDA approval

Geyatee Deshpande Article rating: 3.4

Strides Pharma Sciences announced that the company’s step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has received approval from United States Food & Drug Administration (USFDA) for Ethacrynic Acid tablets USP, 25 mg.

Nifty trend for Wednesday and stocks in news: Reliance Industries, Motherson Sumi Systems, Lasa Supergenerics, Cipla and Indo Count Industries
Nifty trend for Wednesday and stocks in news: Reliance Industries, Motherson Sumi Systems, Lasa Supergenerics, Cipla and Indo Count Industries

Nifty trend for Wednesday and stocks in news: Reliance Industries, Motherson Sumi Systems, Lasa Supergenerics, Cipla and Indo Count Industries

Karan Dsij Article rating: 4.7

The zone of 11,789-11,820 would be a crucial support area in the near term while, on the upside, the bulls need to sustain above the level of 11,950 for the continuation of the upmove.

Indian markets likely to open higher as stimulus talks stay alive!
Indian markets likely to open higher as stimulus talks stay alive!

Indian markets likely to open higher as stimulus talks stay alive!

Karan Dsij Article rating: 4.5

The index has a resistance placed around the levels of 11,950 and until and unless this level is not crossed convincingly, it’s better to refrain from making any heavy long positions in the index. Meanwhile, the broader indices can be looked into for some stock-specific trading opportunities.

Retirement planning: An unpenetrated concept in India
Retirement planning: An unpenetrated concept in India

Retirement planning: An unpenetrated concept in India

Henil Shah Article rating: 3.3

Retirement planning is still an unfamiliar term in India. The idea of making a retirement plan in advance doesn’t even cross in minds of most of the population. Read on to find out more.

Cipla launches Nintib to treat idiopathic pulmonary fibrosis; stock ends in green
Cipla launches Nintib to treat idiopathic pulmonary fibrosis; stock ends in green

Cipla launches Nintib to treat idiopathic pulmonary fibrosis; stock ends in green

Anthony Fernandes Article rating: 4.7

The pharma major, Cipla Limited announced on Tuesday that it has launched generic Nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF), under the brand name, 'Nintib'. The drug will be made available in the form of 100 mg and 150 mg capsules.

Indo Count Industries Ltd forays into bed linen markets; locks in at upper circuit
Indo Count Industries Ltd forays into bed linen markets; locks in at upper circuit

Indo Count Industries Ltd forays into bed linen markets; locks in at upper circuit

Nidhi Jani Article rating: 3.8

Looking at the industrial front, China has a 39 per cent share in home textile exports with USD 19 billion, followed by India at 11 per cent with USD 5 billion. India, being the second largest home textile exporter as well as the largest producer of cotton in the world, is expected to benefit from this structural shift.

Nucleus Software Exports forms bullish engulfing candle
Nucleus Software Exports forms bullish engulfing candle

Nucleus Software Exports forms bullish engulfing candle

Vinayak Gangule Article rating: 4.5

On Tuesday, the stock has formed a bullish engulfing candlestick pattern on the daily timeframe. The bullish engulfing candlestick pattern is considered to be a bullish reversal pattern and usually occurs at the bottom of a downtrend.

RSS
First20692070207120722074207620772078Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR